These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 20967826)

  • 1. Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.
    Syn WK; Choi SS; Liaskou E; Karaca GF; Agboola KM; Oo YH; Mi Z; Pereira TA; Zdanowicz M; Malladi P; Chen Y; Moylan C; Jung Y; Bhattacharya SD; Teaberry V; Omenetti A; Abdelmalek MF; Guy CD; Adams DH; Kuo PC; Michelotti GA; Whitington PF; Diehl AM
    Hepatology; 2011 Jan; 53(1):106-15. PubMed ID: 20967826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.
    Syn WK; Agboola KM; Swiderska M; Michelotti GA; Liaskou E; Pang H; Xie G; Philips G; Chan IS; Karaca GF; Pereira Tde A; Chen Y; Mi Z; Kuo PC; Choi SS; Guy CD; Abdelmalek MF; Diehl AM
    Gut; 2012 Sep; 61(9):1323-9. PubMed ID: 22427237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
    Coombes JD; Choi SS; Swiderska-Syn M; Manka P; Reid DT; Palma E; Briones-Orta MA; Xie G; Younis R; Kitamura N; Della Peruta M; Bitencourt S; Dollé L; Oo YH; Mi Z; Kuo PC; Williams R; Chokshi S; Canbay A; Claridge LC; Eksteen B; Diehl AM; Syn WK
    Biochim Biophys Acta; 2016 Jan; 1862(1):135-44. PubMed ID: 26529285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accumulation of natural killer T cells in progressive nonalcoholic fatty liver disease.
    Syn WK; Oo YH; Pereira TA; Karaca GF; Jung Y; Omenetti A; Witek RP; Choi SS; Guy CD; Fearing CM; Teaberry V; Pereira FE; Adams DH; Diehl AM
    Hepatology; 2010 Jun; 51(6):1998-2007. PubMed ID: 20512988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease.
    Syn WK; Jung Y; Omenetti A; Abdelmalek M; Guy CD; Yang L; Wang J; Witek RP; Fearing CM; Pereira TA; Teaberry V; Choi SS; Conde-Vancells J; Karaca GF; Diehl AM
    Gastroenterology; 2009 Oct; 137(4):1478-1488.e8. PubMed ID: 19577569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model.
    Sahai A; Malladi P; Melin-Aldana H; Green RM; Whitington PF
    Am J Physiol Gastrointest Liver Physiol; 2004 Jul; 287(1):G264-73. PubMed ID: 15044174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression.
    Schulien I; Hockenjos B; Schmitt-Graeff A; Perdekamp MG; Follo M; Thimme R; Hasselblatt P
    Cell Death Differ; 2019 Sep; 26(9):1688-1699. PubMed ID: 30778201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.
    Sahai A; Malladi P; Pan X; Paul R; Melin-Aldana H; Green RM; Whitington PF
    Am J Physiol Gastrointest Liver Physiol; 2004 Nov; 287(5):G1035-43. PubMed ID: 15256362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
    Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
    Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance promotes Lysyl Oxidase Like 2 induction and fibrosis accumulation in non-alcoholic fatty liver disease.
    Dongiovanni P; Meroni M; Baselli GA; Bassani GA; Rametta R; Pietrelli A; Maggioni M; Facciotti F; Trunzo V; Badiali S; Fargion S; Gatti S; Valenti L
    Clin Sci (Lond); 2017 Jun; 131(12):1301-1315. PubMed ID: 28468951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
    Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
    Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Annexin A2-Notch regulatory loop in hepatocytes promotes liver fibrosis in NAFLD by increasing osteopontin expression.
    Wang G; Duan J; Pu G; Ye C; Li Y; Xiu W; Xu J; Liu B; Zhu Y; Wang C
    Biochim Biophys Acta Mol Basis Dis; 2022 Aug; 1868(8):166413. PubMed ID: 35413401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer.
    Wei G; An P; Vaid KA; Nasser I; Huang P; Tan L; Zhao S; Schuppan D; Popov YV
    Am J Physiol Gastrointest Liver Physiol; 2020 Jan; 318(1):G174-G188. PubMed ID: 31630534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling.
    Urtasun R; Lopategi A; George J; Leung TM; Lu Y; Wang X; Ge X; Fiel MI; Nieto N
    Hepatology; 2012 Feb; 55(2):594-608. PubMed ID: 21953216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury.
    Arriazu E; Ge X; Leung TM; Magdaleno F; Lopategi A; Lu Y; Kitamura N; Urtasun R; Theise N; Antoine DJ; Nieto N
    Gut; 2017 Jun; 66(6):1123-1137. PubMed ID: 26818617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteopontin is an important mediator of alcoholic liver disease via hepatic stellate cell activation.
    Seth D; Duly A; Kuo PC; McCaughan GW; Haber PS
    World J Gastroenterol; 2014 Sep; 20(36):13088-104. PubMed ID: 25278703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteopontin is a novel downstream target of SOX9 with diagnostic implications for progression of liver fibrosis in humans.
    Pritchett J; Harvey E; Athwal V; Berry A; Rowe C; Oakley F; Moles A; Mann DA; Bobola N; Sharrocks AD; Thomson BJ; Zaitoun AM; Irving WL; Guha IN; Hanley NA; Hanley KP
    Hepatology; 2012 Sep; 56(3):1108-16. PubMed ID: 22488688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
    Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
    Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin cleavage of osteopontin controls activation of hepatic stellate cells and is essential for liver fibrogenesis.
    Cui G; Chen J; Wu Z; Huang H; Wang L; Liang Y; Zeng P; Yang J; Uede T; Diao H
    J Cell Physiol; 2019 Jun; 234(6):8988-8997. PubMed ID: 30350863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
    Machado MV; Michelotti GA; Pereira Tde A; Boursier J; Kruger L; Swiderska-Syn M; Karaca G; Xie G; Guy CD; Bohinc B; Lindblom KR; Johnson E; Kornbluth S; Diehl AM
    Gut; 2015 Jul; 64(7):1148-57. PubMed ID: 25053716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.